Drug Type Synthetic peptide |
Synonyms 4-(2-Methylanilidocarbamoyl)-phenylacetyl-L-Citrullyl-L-Glutamyl-L-Seryl-L-Valyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-N6-[N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl]-L-Lysyl amide, RAB202 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (United States), Rare Pediatric Disease (United States) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteogenesis Imperfecta | Preclinical | United States | 17 Sep 2026 | |
| Osteoporosis | Preclinical | China | 04 Jun 2025 | |
| Spinal fusion | Preclinical | China | 04 Jun 2025 |






